Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation?
Fiche publication
Date publication
février 2020
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia, Pr BENSOUSSAN Danièle, Dr REPPEL Loïc
Tous les auteurs :
Voisin C, Cauchois G, Reppel L, Laroye C, Louarn L, Schenowitz C, Sonon P, Poras I, Wang V, D Carosella E, Benkirane-Jessel N, Moreau P, Rouas-Freiss N, Bensoussan D, Huselstein C
Lien Pubmed
Résumé
Umbilical mesenchymal stem/stromal cells (MSCs), and especially those derived from Wharton's jelly (WJ), are a promising engineering tool for tissue repair in an allogeneic context. This is due to their differentiation capacity and immunological properties, like their immunomodulatory potential and paracrine activity. Hence, these cells may be considered an Advanced Therapy Medicinal Product (ATMP). The purpose of this work was to differentiate MSCs from WJ (WJ-MSCs) into chondrocytes using a scaffold and to evaluate, in vitro, the immunomodulatory capacities of WJ-MSCs in an allogeneic and inflammatory context, mimicked by IFN-γ and TNF-α priming during the chondrogenic differentiation.
Mots clés
Advanced Therapy Medicinal Product, allogeneic context, cell differentiation, immunomodulation, mesenchymal stem/stromal cells
Référence
J Clin Med. 2020 Feb 4;9(2):